Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers
Apatinib [Aitan ® (brand name in China)], also known as rivoceranib, is a novel, small molecule, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor and is the second anti-angiogenic drug to be approved in China for the treatment of advanced or metastatic gast...
Gespeichert in:
| Veröffentlicht in: | Drugs (New York, N.Y.) N.Y.), 2018-05, Vol.78 (7), p.747-758 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 758 |
|---|---|
| container_issue | 7 |
| container_start_page | 747 |
| container_title | Drugs (New York, N.Y.) |
| container_volume | 78 |
| creator | Scott, Lesley J. |
| description | Apatinib [Aitan
®
(brand name in China)], also known as rivoceranib, is a novel, small molecule, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor and is the second anti-angiogenic drug to be approved in China for the treatment of advanced or metastatic gastric cancer. This article summarizes the pharmacological properties of apatinib and reviews its clinical use in chemotherapy-experienced patients with advanced gastric adenocarcinoma, including gastroesophageal adenocarcinoma (GEA), or with other advanced cancers such as non-small cell lung cancer (NSCLC), breast cancer, gynaecological cancers, hepatocellular carcinoma (HCC), thyroid cancer and sarcomas. As third- or subsequent-line therapy, oral apatinib significantly prolonged median progression-free survival (PFS) and overall survival (OS) compared with placebo and had a manageable safety profile in Chinese patients with advanced or metastatic gastric cancer or GEA participating in randomized, double-blind, multicentre, phase 2 and 3 trials. More limited evidence also supports it use as subsequent-line treatment in Chinese patients with other advanced or metastatic solid tumours, including NSCLC, breast cancer and HCC. Further clinical experience and long-term pharmacovigilance data are required to more definitively establish the efficacy and safety profile of apatinib, including its use in combination with other chemotherapy agents and its role in the management of other types of advanced or metastatic solid tumours. In the meantime, given its convenient administration regimen and the limited treatment options and poor prognosis for patients with advanced or metastatic solid tumours, apatinib is an important, emerging treatment option for adult patients with advanced gastric adenocarcinoma or GEA who have progressed or relapsed after chemotherapy. |
| doi_str_mv | 10.1007/s40265-018-0903-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2026415162</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2140868979</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-4d845ebe76517b68bf27eb77b70b232a0611c7a4674155bc51fd1109d24731303</originalsourceid><addsrcrecordid>eNp1kEFLwzAYhoMobk5_gBcpePESzZemSeOtDN2EwUD0HJI21Y6tnUk78d-b0jlB8JR8fM_7JjwIXQK5BULEnWeE8gQTSDGRJMbyCI0BhMQgE3KMxoQAxZxzMUJn3q_6USbyFI2o5DymEsZonm11W9WVuY-y6NnuKvsZVXWUFTtd57aIZtq3rsqjaT-6SNdFtGzfw-1ADBt_jk5Kvfb2Yn9O0Ovjw8t0jhfL2dM0W-CcxWmLWZGyxBoreALC8NSUVFgjhBHE0JhqwgFyoRkXDJLE5AmUBQCRBWUihpjEE3Qz9G5d89FZ36pN5XO7XuvaNp1XNCgJUeA0oNd_0FXTuTr8TlFgJOWpFDJQMFC5a7x3tlRbV220-1JAVK9ZDZpV0Kx6zarPXO2bO7OxxSHx4zUAdAB8WNVv1v0-_X_rN1SehAw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2140868979</pqid></control><display><type>article</type><title>Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Scott, Lesley J.</creator><creatorcontrib>Scott, Lesley J.</creatorcontrib><description>Apatinib [Aitan
®
(brand name in China)], also known as rivoceranib, is a novel, small molecule, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor and is the second anti-angiogenic drug to be approved in China for the treatment of advanced or metastatic gastric cancer. This article summarizes the pharmacological properties of apatinib and reviews its clinical use in chemotherapy-experienced patients with advanced gastric adenocarcinoma, including gastroesophageal adenocarcinoma (GEA), or with other advanced cancers such as non-small cell lung cancer (NSCLC), breast cancer, gynaecological cancers, hepatocellular carcinoma (HCC), thyroid cancer and sarcomas. As third- or subsequent-line therapy, oral apatinib significantly prolonged median progression-free survival (PFS) and overall survival (OS) compared with placebo and had a manageable safety profile in Chinese patients with advanced or metastatic gastric cancer or GEA participating in randomized, double-blind, multicentre, phase 2 and 3 trials. More limited evidence also supports it use as subsequent-line treatment in Chinese patients with other advanced or metastatic solid tumours, including NSCLC, breast cancer and HCC. Further clinical experience and long-term pharmacovigilance data are required to more definitively establish the efficacy and safety profile of apatinib, including its use in combination with other chemotherapy agents and its role in the management of other types of advanced or metastatic solid tumours. In the meantime, given its convenient administration regimen and the limited treatment options and poor prognosis for patients with advanced or metastatic solid tumours, apatinib is an important, emerging treatment option for adult patients with advanced gastric adenocarcinoma or GEA who have progressed or relapsed after chemotherapy.</description><identifier>ISSN: 0012-6667</identifier><identifier>EISSN: 1179-1950</identifier><identifier>DOI: 10.1007/s40265-018-0903-9</identifier><identifier>PMID: 29663291</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Adenocarcinoma ; Adis Drug Evaluation ; Angiogenesis ; Antineoplastic Agents - therapeutic use ; Apoptosis ; Biomarkers ; Bone cancer ; Brand names ; Breast cancer ; Cancer ; Cancer therapies ; Cell adhesion & migration ; Chemotherapy ; Clinical medicine ; Clinical trials ; Cost analysis ; Drugs ; Enzyme inhibitors ; Gastric cancer ; Growth factors ; Gynecology ; Humans ; Internal Medicine ; Liver cancer ; Lung cancer ; Medical prognosis ; Medicine ; Medicine & Public Health ; Metastases ; Metastasis ; Neoplasms - drug therapy ; Neoplasms - pathology ; Non-small cell lung carcinoma ; Patients ; Pharmacology ; Pharmacology/Toxicology ; Pharmacotherapy ; Pharmacovigilance ; Phosphorylation ; Physiology ; Protein Kinase Inhibitors - therapeutic use ; Protein-tyrosine kinase ; Pyridines - therapeutic use ; Safety management ; Solid tumors ; Stomach Neoplasms - drug therapy ; Stomach Neoplasms - pathology ; Survival ; Thyroid ; Thyroid cancer ; Treatment Outcome ; Tumors ; Tyrosine ; Vascular endothelial growth factor ; Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors ; Vascular endothelial growth factor receptors</subject><ispartof>Drugs (New York, N.Y.), 2018-05, Vol.78 (7), p.747-758</ispartof><rights>Springer International Publishing AG, part of Springer Nature 2018. corrected publication May 2018</rights><rights>Copyright Springer Science & Business Media May 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-4d845ebe76517b68bf27eb77b70b232a0611c7a4674155bc51fd1109d24731303</citedby><cites>FETCH-LOGICAL-c438t-4d845ebe76517b68bf27eb77b70b232a0611c7a4674155bc51fd1109d24731303</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40265-018-0903-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s40265-018-0903-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29663291$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Scott, Lesley J.</creatorcontrib><title>Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers</title><title>Drugs (New York, N.Y.)</title><addtitle>Drugs</addtitle><addtitle>Drugs</addtitle><description>Apatinib [Aitan
®
(brand name in China)], also known as rivoceranib, is a novel, small molecule, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor and is the second anti-angiogenic drug to be approved in China for the treatment of advanced or metastatic gastric cancer. This article summarizes the pharmacological properties of apatinib and reviews its clinical use in chemotherapy-experienced patients with advanced gastric adenocarcinoma, including gastroesophageal adenocarcinoma (GEA), or with other advanced cancers such as non-small cell lung cancer (NSCLC), breast cancer, gynaecological cancers, hepatocellular carcinoma (HCC), thyroid cancer and sarcomas. As third- or subsequent-line therapy, oral apatinib significantly prolonged median progression-free survival (PFS) and overall survival (OS) compared with placebo and had a manageable safety profile in Chinese patients with advanced or metastatic gastric cancer or GEA participating in randomized, double-blind, multicentre, phase 2 and 3 trials. More limited evidence also supports it use as subsequent-line treatment in Chinese patients with other advanced or metastatic solid tumours, including NSCLC, breast cancer and HCC. Further clinical experience and long-term pharmacovigilance data are required to more definitively establish the efficacy and safety profile of apatinib, including its use in combination with other chemotherapy agents and its role in the management of other types of advanced or metastatic solid tumours. In the meantime, given its convenient administration regimen and the limited treatment options and poor prognosis for patients with advanced or metastatic solid tumours, apatinib is an important, emerging treatment option for adult patients with advanced gastric adenocarcinoma or GEA who have progressed or relapsed after chemotherapy.</description><subject>Adenocarcinoma</subject><subject>Adis Drug Evaluation</subject><subject>Angiogenesis</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Apoptosis</subject><subject>Biomarkers</subject><subject>Bone cancer</subject><subject>Brand names</subject><subject>Breast cancer</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Cell adhesion & migration</subject><subject>Chemotherapy</subject><subject>Clinical medicine</subject><subject>Clinical trials</subject><subject>Cost analysis</subject><subject>Drugs</subject><subject>Enzyme inhibitors</subject><subject>Gastric cancer</subject><subject>Growth factors</subject><subject>Gynecology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Liver cancer</subject><subject>Lung cancer</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - pathology</subject><subject>Non-small cell lung carcinoma</subject><subject>Patients</subject><subject>Pharmacology</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacotherapy</subject><subject>Pharmacovigilance</subject><subject>Phosphorylation</subject><subject>Physiology</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Protein-tyrosine kinase</subject><subject>Pyridines - therapeutic use</subject><subject>Safety management</subject><subject>Solid tumors</subject><subject>Stomach Neoplasms - drug therapy</subject><subject>Stomach Neoplasms - pathology</subject><subject>Survival</subject><subject>Thyroid</subject><subject>Thyroid cancer</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><subject>Tyrosine</subject><subject>Vascular endothelial growth factor</subject><subject>Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors</subject><subject>Vascular endothelial growth factor receptors</subject><issn>0012-6667</issn><issn>1179-1950</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kEFLwzAYhoMobk5_gBcpePESzZemSeOtDN2EwUD0HJI21Y6tnUk78d-b0jlB8JR8fM_7JjwIXQK5BULEnWeE8gQTSDGRJMbyCI0BhMQgE3KMxoQAxZxzMUJn3q_6USbyFI2o5DymEsZonm11W9WVuY-y6NnuKvsZVXWUFTtd57aIZtq3rsqjaT-6SNdFtGzfw-1ADBt_jk5Kvfb2Yn9O0Ovjw8t0jhfL2dM0W-CcxWmLWZGyxBoreALC8NSUVFgjhBHE0JhqwgFyoRkXDJLE5AmUBQCRBWUihpjEE3Qz9G5d89FZ36pN5XO7XuvaNp1XNCgJUeA0oNd_0FXTuTr8TlFgJOWpFDJQMFC5a7x3tlRbV220-1JAVK9ZDZpV0Kx6zarPXO2bO7OxxSHx4zUAdAB8WNVv1v0-_X_rN1SehAw</recordid><startdate>20180501</startdate><enddate>20180501</enddate><creator>Scott, Lesley J.</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>7QO</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20180501</creationdate><title>Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers</title><author>Scott, Lesley J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-4d845ebe76517b68bf27eb77b70b232a0611c7a4674155bc51fd1109d24731303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adenocarcinoma</topic><topic>Adis Drug Evaluation</topic><topic>Angiogenesis</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Apoptosis</topic><topic>Biomarkers</topic><topic>Bone cancer</topic><topic>Brand names</topic><topic>Breast cancer</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Cell adhesion & migration</topic><topic>Chemotherapy</topic><topic>Clinical medicine</topic><topic>Clinical trials</topic><topic>Cost analysis</topic><topic>Drugs</topic><topic>Enzyme inhibitors</topic><topic>Gastric cancer</topic><topic>Growth factors</topic><topic>Gynecology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Liver cancer</topic><topic>Lung cancer</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - pathology</topic><topic>Non-small cell lung carcinoma</topic><topic>Patients</topic><topic>Pharmacology</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacotherapy</topic><topic>Pharmacovigilance</topic><topic>Phosphorylation</topic><topic>Physiology</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Protein-tyrosine kinase</topic><topic>Pyridines - therapeutic use</topic><topic>Safety management</topic><topic>Solid tumors</topic><topic>Stomach Neoplasms - drug therapy</topic><topic>Stomach Neoplasms - pathology</topic><topic>Survival</topic><topic>Thyroid</topic><topic>Thyroid cancer</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><topic>Tyrosine</topic><topic>Vascular endothelial growth factor</topic><topic>Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors</topic><topic>Vascular endothelial growth factor receptors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Scott, Lesley J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Drugs (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Scott, Lesley J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers</atitle><jtitle>Drugs (New York, N.Y.)</jtitle><stitle>Drugs</stitle><addtitle>Drugs</addtitle><date>2018-05-01</date><risdate>2018</risdate><volume>78</volume><issue>7</issue><spage>747</spage><epage>758</epage><pages>747-758</pages><issn>0012-6667</issn><eissn>1179-1950</eissn><abstract>Apatinib [Aitan
®
(brand name in China)], also known as rivoceranib, is a novel, small molecule, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor and is the second anti-angiogenic drug to be approved in China for the treatment of advanced or metastatic gastric cancer. This article summarizes the pharmacological properties of apatinib and reviews its clinical use in chemotherapy-experienced patients with advanced gastric adenocarcinoma, including gastroesophageal adenocarcinoma (GEA), or with other advanced cancers such as non-small cell lung cancer (NSCLC), breast cancer, gynaecological cancers, hepatocellular carcinoma (HCC), thyroid cancer and sarcomas. As third- or subsequent-line therapy, oral apatinib significantly prolonged median progression-free survival (PFS) and overall survival (OS) compared with placebo and had a manageable safety profile in Chinese patients with advanced or metastatic gastric cancer or GEA participating in randomized, double-blind, multicentre, phase 2 and 3 trials. More limited evidence also supports it use as subsequent-line treatment in Chinese patients with other advanced or metastatic solid tumours, including NSCLC, breast cancer and HCC. Further clinical experience and long-term pharmacovigilance data are required to more definitively establish the efficacy and safety profile of apatinib, including its use in combination with other chemotherapy agents and its role in the management of other types of advanced or metastatic solid tumours. In the meantime, given its convenient administration regimen and the limited treatment options and poor prognosis for patients with advanced or metastatic solid tumours, apatinib is an important, emerging treatment option for adult patients with advanced gastric adenocarcinoma or GEA who have progressed or relapsed after chemotherapy.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>29663291</pmid><doi>10.1007/s40265-018-0903-9</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-6667 |
| ispartof | Drugs (New York, N.Y.), 2018-05, Vol.78 (7), p.747-758 |
| issn | 0012-6667 1179-1950 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2026415162 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Adenocarcinoma Adis Drug Evaluation Angiogenesis Antineoplastic Agents - therapeutic use Apoptosis Biomarkers Bone cancer Brand names Breast cancer Cancer Cancer therapies Cell adhesion & migration Chemotherapy Clinical medicine Clinical trials Cost analysis Drugs Enzyme inhibitors Gastric cancer Growth factors Gynecology Humans Internal Medicine Liver cancer Lung cancer Medical prognosis Medicine Medicine & Public Health Metastases Metastasis Neoplasms - drug therapy Neoplasms - pathology Non-small cell lung carcinoma Patients Pharmacology Pharmacology/Toxicology Pharmacotherapy Pharmacovigilance Phosphorylation Physiology Protein Kinase Inhibitors - therapeutic use Protein-tyrosine kinase Pyridines - therapeutic use Safety management Solid tumors Stomach Neoplasms - drug therapy Stomach Neoplasms - pathology Survival Thyroid Thyroid cancer Treatment Outcome Tumors Tyrosine Vascular endothelial growth factor Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors Vascular endothelial growth factor receptors |
| title | Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T17%3A58%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Apatinib:%20A%20Review%20in%20Advanced%20Gastric%20Cancer%20and%20Other%20Advanced%20Cancers&rft.jtitle=Drugs%20(New%20York,%20N.Y.)&rft.au=Scott,%20Lesley%20J.&rft.date=2018-05-01&rft.volume=78&rft.issue=7&rft.spage=747&rft.epage=758&rft.pages=747-758&rft.issn=0012-6667&rft.eissn=1179-1950&rft_id=info:doi/10.1007/s40265-018-0903-9&rft_dat=%3Cproquest_cross%3E2140868979%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2140868979&rft_id=info:pmid/29663291&rfr_iscdi=true |